216 related articles for article (PubMed ID: 2608162)
1. The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat.
De Sarno P; Pomponi M; Giacobini E; Tang XC; Williams E
Neurochem Res; 1989 Oct; 14(10):971-7. PubMed ID: 2608162
[TBL] [Abstract][Full Text] [Related]
2. The long-acting cholinesterase inhibitor heptyl-physostigmine attenuates the scopolamine-induced learning impairment of rats in a 14-unit T-maze.
Iijima S; Greig NH; Garofalo P; Spangler EL; Heller B; Brossi A; Ingram DK
Neurosci Lett; 1992 Sep; 144(1-2):79-83. PubMed ID: 1436716
[TBL] [Abstract][Full Text] [Related]
3. Effect of huperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the rat.
Tang XC; De Sarno P; Sugaya K; Giacobini E
J Neurosci Res; 1989 Oct; 24(2):276-85. PubMed ID: 2585551
[TBL] [Abstract][Full Text] [Related]
4. Relation of brain regional physostigmine concentration to cholinesterase activity and acetylcholine and choline levels in rat.
Hallak M; Giacobini E
Neurochem Res; 1986 Jul; 11(7):1037-48. PubMed ID: 3748273
[TBL] [Abstract][Full Text] [Related]
5. Reversal of cognitive impairment by heptyl physostigmine, a long-lasting cholinesterase inhibitor, in primates.
Rupniak NM; Tye SJ; Brazell C; Heald A; Iversen SD; Pagella PG
J Neurol Sci; 1992 Feb; 107(2):246-9. PubMed ID: 1564524
[TBL] [Abstract][Full Text] [Related]
6. Effect of cholinesterase inhibitor and exercise on choline acetyltransferase and acetylcholinesterase activities in rat brain regions.
Somani SM; Babu SR; Arneric SP; Dube SN
Pharmacol Biochem Behav; 1991 Jun; 39(2):337-43. PubMed ID: 1946575
[TBL] [Abstract][Full Text] [Related]
7. Species- and concentration-dependent differences of acetyl- and butyrylcholinesterase sensitivity to physostigmine and neostigmine.
Bitzinger DI; Gruber M; Tümmler S; Michels B; Bundscherer A; Hopf S; Trabold B; Graf BM; Zausig YA
Neuropharmacology; 2016 Oct; 109():1-6. PubMed ID: 26772968
[TBL] [Abstract][Full Text] [Related]
8. Heptyl-physostigmine enhances basal forebrain control of cortical cerebral blood flow.
Linville DG; Giacobini E; Arnerić SP
J Neurosci Res; 1992 Mar; 31(3):573-7. PubMed ID: 1640506
[TBL] [Abstract][Full Text] [Related]
9. The effects of physostigmine on acetylcholinesterase activity of CSF plasma and brain. A comparison of intravenous and intraventricular administration in beagle dogs.
Mattio T; McIlhany M; Giacobini E; Hallak M
Neuropharmacology; 1986 Oct; 25(10):1167-77. PubMed ID: 3785584
[TBL] [Abstract][Full Text] [Related]
10. Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies.
Braida D; Sala M
CNS Drug Rev; 2001; 7(4):369-86. PubMed ID: 11830755
[TBL] [Abstract][Full Text] [Related]
11. Acetylcholinesterase inhibition and anti-soman efficacy of homologs of physostigmine.
Harris LW; Anderson DR; Pastelak AM; Bowersox SL; Vanderpool BA; Lennox WJ
Drug Chem Toxicol; 1992; 15(2):127-43. PubMed ID: 1597127
[TBL] [Abstract][Full Text] [Related]
12. Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
Lane RM; Potkin SG; Enz A
Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human brain and RBC acetylcholinesterase (AChE) by heptylphysostigmine (HPTL).
Moriearty PL; Becker RE
Methods Find Exp Clin Pharmacol; 1992 Oct; 14(8):615-21. PubMed ID: 1494302
[TBL] [Abstract][Full Text] [Related]
14. Cholinesterase inhibitor effects on neurotransmitters in rat cortex in vivo.
Cuadra G; Summers K; Giacobini E
J Pharmacol Exp Ther; 1994 Jul; 270(1):277-84. PubMed ID: 7913496
[TBL] [Abstract][Full Text] [Related]
15. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex.
Mori F; Lai CC; Fusi F; Giacobini E
Neuroreport; 1995 Mar; 6(4):633-6. PubMed ID: 7605915
[TBL] [Abstract][Full Text] [Related]
16. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
Rakonczay Z
Acta Biol Hung; 2003; 54(2):183-9. PubMed ID: 14535624
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the decarbamoylation rates of physostigmine-inhibited plasma and red cell cholinesterases of man with other species.
Wetherell JR; French MC
Biochem Pharmacol; 1991 Jul; 42(3):515-20. PubMed ID: 1907148
[TBL] [Abstract][Full Text] [Related]
18. The effect of cholinesterase inhibitors on the secretion of APPS from rat brain cortex.
Giacobini E; Mori F; Lai CC
Ann N Y Acad Sci; 1996 Jan; 777():393-8. PubMed ID: 8624119
[TBL] [Abstract][Full Text] [Related]
19. The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics.
Greig NH; De Micheli E; Holloway HW; Yu QS; Utsuki T; Perry TA; Brossi A; Ingram DK; Deutsch J; Lahiri DK; Soncrant TT
Acta Neurol Scand Suppl; 2000; 176():74-84. PubMed ID: 11261809
[TBL] [Abstract][Full Text] [Related]
20. Acetylcholinesterase inhibitors block acetylcholine-evoked release of dopamine in rat striatum, in vivo.
Dajas-Bailador F; Costa G; Emmett S; Bonilla C; Dajas F
Brain Res; 1996 May; 722(1-2):12-8. PubMed ID: 8813345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
